ClinicalTrials.gg

Program

HDM2005

A development code. Also written as “Phase Ib Cohort 1: HDM2005 1.2 mg/kg + R-Len”, “Phase Ib Cohort 2: HDM2005 1.4 mg/kg + R-Len” and “HDM2005 plus rituximab and lenalidomide”.

Its studies are mostly in Lymphoma, Mantle-Cell · Lymphoma, led by Huadong Medicine.

Furthest: phase 1, since Sep 19, 20243 company-led studies, 3 open or runningNext primary completion: Jul 1, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Huadong Medicine33 open or runningphase 1since Sep 19, 2024Sep 19, 2024Jul 1, 2027phase 1 · NCT07004296

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 19, 2024First study: phase 1 study in LymphomaFirst studyNCT06615193 · 111 planned · China
  2. May 27, 2025Phase 1 study in Advanced Solid TumorsNCT07004296 · 72 planned · China
  3. Jul 2, 2026Phase 1 study in Lymphoma, Mantle-CellNCT07697339 · 40 planned

Ahead

  1. Jul 1, 2027Primary completion: phase 1 study in Advanced Solid TumorsNCT07004296
  2. Aug 10, 2027Primary completion: phase 1 study in Lymphoma, Mantle-CellNCT07697339

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07697339Lymphoma, Mantle-Cell1Not yet recruitingAug 10, 202740
NCT07004296Advanced Solid Tumors · China1RecruitingJul 1, 202772
NCT06615193Lymphoma · China1RecruitingJun 24, 2026111

How it is read

Names in the registry

  • “HDM2005”, 2 entries
  • “Phase Ib Cohort 1: HDM2005 1.2 mg/kg + R-Len”, 1 entry
  • “Phase Ib Cohort 2: HDM2005 1.4 mg/kg + R-Len”, 1 entry
  • “HDM2005 plus rituximab and lenalidomide”, 1 entry

Codes read as this program: HDM2005.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.